Amyloid‐β protein (Aβ) Glu11 is the major β‐secretase site of β‐site amyloid‐β precursor protein‐cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis

Cleavage of amyloid‐β precursor protein (APP) at the Asp1 β‐secretase site of the amyloid‐β protein (Aβ) domain by β‐site Aβ precursor protein‐cleaving enzyme 1 (BACE1) is required for the generation of Aβ, a central component of neuritic plaques in the Alzheimer's disease (AD) brain. In this study, we found that Aβ Glu11 is the major β‐secretase site for cleavage of APP by BACE1 to generate soluble secreted APP (sAPPβ)606 and the C‐terminal membrane‐bound fragment (CTF)β product C89. Cleavage of C89 by γ‐secretase resulted in truncated Aβ generation in a non‐amyloidogenic pathway. A familial AD‐associated Swedish APP mutation adjacent to Aβ Asp1 shifted the major APP β‐secretase cleavage site from Aβ Glu11 to Asp1, resulting in significant increases in sAPPβ596 and CTFβ C99 generation and the C99/89 ratio, in turn leading to increased Aβ production in cultured cells in vitro and transgenic AD model mouse brains in vivo. Furthermore, increased BACE1 expression facilitated APP being processed by the β‐secretase processing pathway rather than the α‐secretase pathway, leading to more Aβ production. Our results suggest that potentiating BACE1 cleavage of APP at both the Asp1 and Glu11 sites, or shifting the cleavage from the Glu11 site to the Asp1 site, could result in increased Aβ production and facilitate neuritic plaque formation. Our study provides new insights into how alteration of BACE1 expression and β‐secretase cleavage site selection could contribute to Alzheimer pathogenesis and the pharmaceutical potential of modulating BACE1 expression and its cleavage site selection.

[1]  Ayae Kinoshita,et al.  Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. , 2013, The Journal of clinical investigation.

[2]  R. Morishita,et al.  Differential Regulation of Amyloid Precursor Protein/Presenilin 1 Interaction during Ab40/42 Production Detected Using Fusion Constructs , 2012, PloS one.

[3]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[4]  Weihong Song,et al.  The role of TMP21 in trafficking and amyloid-β precursor protein (APP) processing in Alzheimer's disease. , 2012, Current Alzheimer research.

[5]  B. de Strooper,et al.  The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing , 2011, Journal of neurochemistry.

[6]  K. Blennow,et al.  Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease , 2010, PloS one.

[7]  S. Bastianetto,et al.  Faculty Opinions recommendation of SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. , 2010 .

[8]  Inna Kuperstein,et al.  Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio , 2010, The EMBO journal.

[9]  L. Guarente,et al.  RETRACTED: SIRT1 Suppresses β-Amyloid Production by Activating the α-Secretase Gene ADAM10 , 2010, Cell.

[10]  H. Soininen,et al.  Plasma Aβ42 and Aβ40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  Hong Qing,et al.  Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression , 2006, Proceedings of the National Academy of Sciences.

[12]  H. Qing,et al.  Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Xiulian Sun,et al.  BACE2, as a novel APP θ‐secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Weihui Zhou,et al.  Leaky Scanning and Reinitiation Regulate BACE1 Gene Expression , 2006, Alzheimer's & Dementia.

[15]  Y. Li,et al.  The FASEB Journal • Research Communication Control of APP processing and A � generation level by , 2022 .

[16]  H. Qing,et al.  Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  H. Qing,et al.  Degradation of BACE by the ubiquitin‐proteasome pathway , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  C. Haass,et al.  Expression of the Alzheimer protease BACE1 is suppressed via its 5'‐untranslated region , 2004, EMBO reports.

[19]  G. Edelman,et al.  Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Marija Mihailovich,et al.  Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. , 2004, Nucleic acids research.

[21]  Hong Qing,et al.  Transcriptional Regulation of BACE1, the β-Amyloid Precursor Protein β-Secretase, by Sp1 , 2004, Molecular and Cellular Biology.

[22]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[23]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[24]  Rudolph E. Tanzi,et al.  BACE Maps to Chromosome 11 and a BACE Homolog, BACE2, Reside in the Obligate Down Syndrome Region of Chromosome 21 , 1999 .

[25]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[26]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[28]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[29]  E M Wijsman,et al.  A familial Alzheimer's disease locus on chromosome 1 , 1995, Science.

[30]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[31]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[32]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[33]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[34]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[35]  S. Shiojiri,et al.  Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity , 1988, Nature.

[36]  L. Villa-komaroff,et al.  Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease , 1988, Nature.

[37]  B. Greenberg,et al.  A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors , 1988, Nature.

[38]  H. Wiśniewski,et al.  Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. S. St George-Hyslop,et al.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. , 1987, Science.

[40]  M. Lerman,et al.  Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. , 1987, Science.

[41]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[42]  H. Qing,et al.  Valproic acid inhibits Aβ production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models , 2008, The Journal of Experimental Medicine.

[43]  Hong Qing,et al.  Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. , 2004, Molecular and cellular biology.

[44]  C. Southan,et al.  Identification of a novel aspartic protease (Asp 2) as beta-secretase. , 1999, Molecular and cellular neurosciences.

[45]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[46]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[47]  D. Selkoe,et al.  Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. , 1992, Nature.

[48]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.